STX17-AS1

Across TCGA pan-cancer cohorts, STX17-AS1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of STX17-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where STX17-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types STX17-AS1 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, KICH, and THCA are the cancer types where STX17-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STX17-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	II,III,IV	−0.512	<.001	10	view →
KICH	Male	All	−1.287	<.001	8	view →
THCA	Male	All	−0.495	<.001	6	view →
COAD	Male	All	+0.527	.011	4	view →
BRCA	Female	All	−0.300	<.001	4	view →
HNSC	All	All	−0.346	.024	3	view →
UCEC	All	All	+0.813	<.001	2	view →
KIRP	All	All	−0.418	.001	2	view →
PRAD	All	All	+0.232	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

STX17-AS1–KIRC

Open the KIRC breakdown →